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THE EXPANDING ROLE OF THE PHARMACIST UNDER THE PATIENT 
PROTECTION AND AFFORDABLE CARE ACT OF 2010 
 
MYUNGSUN RO 
ABSTRACT 
The Patient Protection and Affordable Care Act (PPACA) represents one of the 
most significant pieces of legislation in the history of United States healthcare. The 
PPACA has two main goals: to increase the insured patient population in the US and to 
reduce the overall cost while improving the quality of healthcare in the US. To 
accomplish the latter goal, healthcare providers are experiencing a movement toward 
integrated, team-oriented models that place increasing accountability on the providers 
and institutions. At the same time, these integrative models emphasize effective 
preventive care, which is critical in reducing the country’s overall healthcare costs. As 
more health care institutions and providers across the country adopt the healthcare reform 
models of the Patient-Centered Medical Homes (PCMH) and Accountable Care 
Organizations (ACOs) directly under the PPACA, the demand for pharmacists is 
increasing. In addition, the role of the pharmacist through Medication Therapy 
Management (MTM) is growing as more public and private sectors adopt MTM and its 
standards are being used as the medication-related cornerstone for the ACOs. There is a 
call for lower costs and higher quality outcomes in healthcare, and the pharmacists are 
increasingly integrated into direct patient care and medication management. The newly 
integrated responsibilities of the pharmacist are numerous and almost limitless. The role 
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of pharmacists is expanding, and as many studies suggest, their contributions produce 
auspicious results. 
  
		 vii 
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………... i 
COPYRIGHT PAGE……………………………………………………………………... ii 
READER APPROVAL PAGE………………………………………………………….. iii 
ACKNOWLEDGMENTS ................................................................................................. iv	
ABSTRACT ........................................................................................................................ v	
TABLE OF CONTENTS .................................................................................................. vii	
LIST OF TABLES ............................................................................................................ iix	
LIST OF FIGURES ........................................................................................................... xi	
LIST OF ABBREVIATIONS .......................................................................................... xiii	
INTRODUCTION .............................................................................................................. 1 
The Unsustainable Cost of US Health Care ................................................................ 1 
Medication-Related Problems and Their Costly Consequences ................................. 3 
Qualification of the Pharmacist .................................................................................. 4 
THE PATIENT PROTECTION AND AFFORDABLE CARE ACT ................................ 5 
PATIENT CENTERED MEDICAL HOME ...................................................................... 6	
PHARMACISTS IN CURRENT PCMH ........................................................................... 7	
Medication Review ..................................................................................................... 7 
Patient Education at Discharge ................................................................................... 8 
		 viii 
Medication Conversion ............................................................................................... 9 
Monitoring ................................................................................................................ 10 
Medication Plan ........................................................................................................ 11 
Outcomes by the Pharmacist in the PCMH Setting .................................................. 12 
ACCOUNTABLE CARE ORGANIZATION .................................................................. 20	
PHARMACISTS IN CURRENT ACOs ........................................................................... 26	
VALUE-BASED PURCHASING MODELS .................................................................. 31	
MEDICATION THERAPY MANAGEMENT ................................................................ 33	
COMMUNITY PHARMACIES ....................................................................................... 36	
DIFFICULTIES ................................................................................................................ 42	
CONCLUSION ................................................................................................................. 52	
REFERENCES ................................................................................................................. 54	
VITA ................................................................................................................................. 64	
 
  
		 ix 
LIST OF TABLES 
 
 
Table Title Page 
1 Intervention Methods and Cost Avoidance of 
Interventions by the UMC Pharmacist 
13 
2 Time Spent Completing Interventions at UMC 14 
3 Cost Avoidance of Interventions Involving Adverse Drug 
Events at UMC 
14 
4 Pharmacist-Led Hospital Interventions and Their 
Outcomes 
17 
5 Interventions Conducted by Clinical Pharmacists in Table 
4 
19 
6 Quality Standards for MSSP 21 
7 Required Competencies for ACOs 25 
8 Interventions Performed by Pharmacists at El Rio Health 
Center ACO 
27 
9 Revenue from Annual Wellness Visits and Services 
Provided  
28 
10 Revenue from Other Services During AWV 28 
11 Medication Therapy Management Components as 
Described in Section 3503 of the Affordable Care Act 
34 
		 x 
12 Five Core Elements of MTM 35 
13 Barriers that Pharmacists Face in Improving Medication 
Therapy 
45 
   
   
 
 
  
		 xi 
LIST OF FIGURES 
 
 
 
Figure Title Page 
1 National Health Expenditure by Year 1 
2 Collective Savings Generated by the Pioneer ACOs 
During the Years of Operation 
23 
3 Collective Savings Held Under the Target Spending and 
the Earned Performance Payments 
24 
4 Flow Chart for TMIs 38 
5 Revenue Generated Per Hour of TMI 39 
6 Acceptance Rates of TMIs 44 
7 PPACA Remains One of the Top Concerns to American 
Voters as of January, 2016 
47 
8 Percentage of the Registered Voters by Political Parties 
Who Consider the Issue of Health Care “the Single Most 
Factor” or “a Very Important Factor” in the 2016 
Elections 
48 
9 Public Awareness of President Obama’s Veto 49 
10 The Persistence of PPACA Opponents 50 
11 Controlling and Reducing Health Care Costs as Polled by 
Providers 
51 
		 xii 
12 Nation’s Favorable View Toward Coordinated Delivery 
of Primary Care 
53 
  
		 xiii 
LIST OF ABBREVIATIONS 
 
ACA ...................................................................................................... Affordable Care Act 
ACO .................................................................................... Accountable Care Organization 
ADE ...................................................................................................... Adverse Drug Event 
AHRQ ............................................................ Agency for Healthcare Research and Quality 
AWV ................................................................................................. Annual Wellness Visit 
CAP ................................................................................. Community-Acquired Pneumonia 
CMS ............................................................... Centers for Medicare and Medicaid Services 
CPOE ......................................................................... Computerized Physician Order Entry 
CPT ................................................................................... Current Procedural Terminology 
DI .............................................................................................................. Drug Information 
DTCC ...................................................................................... Diabetes Ten City Challenge 
DVT ................................................................................................. Deep Vein Thrombosis 
ED ................................................................................................... Emergency Department 
EMR .......................................................................................... Electronic Medical Records 
FFS ............................................................................................................... Fee-For-Service 
GDP ............................................................................................... Gross Domestic Product 
HEDIS .................................................. Healthcare Effectiveness Data and Information Set 
HTN ................................................................................................................. Hypertension 
ICU ......................................................................................................... Intensive Care Unit 
IOM ...................................................................................................... Institute of Medicine 
LOS ................................................................................................................ Length of Stay 
		 xiv 
MAP .................................................................................... Medication-related Action Plan 
MCA ......................................................................................... Medication Cost Avoidance 
MSSP ............................................................................. Medicare Shared Savings Program 
MTM ............................................................................... Medication Therapy Management 
MTR ......................................................................................... Medication Therapy Review 
NCQA ............................................................... National Committee for Quality Assurance 
P4P ....................................................................................................... Pay-for-Performance 
PCCPS ........................................................................ Primary Care Pharmacist Specialists 
PCMH ................................................................................ Patient Centered Medical Home 
PharmD ................................................................................................. Doctor of Pharmacy 
PMR ......................................................................................... Personal Medication Record 
PPACA ............................................................. Patient Protection and Affordable Care Act 
TDM ....................................................................................... Therapeutic Drug Monitoring 
TMI .................................................................................. Targeted Medication Intervention 
TOC......................................................................................................... Transitions of Care 
UMC ........................................................................................... University Medical Center 
VBP ................................................................................................ Value-Based Purchasing 
 
 
 
 
 
	1 
INTRODUCTION 
 
The Unsustainable Cost of US Health Care 
 Currently, the cost of US health care is skyrocketing and readily accepted as 
unsustainable.1 According to the Centers for Medicare and Medicaid Services (CMS), the 
national health expenditure totaled more than $2.9 billion in 2013, which amounted to 
17.4% of the Gross Domestic Product (GDP) for that year.2 Furthermore, CMS predicts 
that the national health expenditure will experience an average 5.8% increase per year, 
and by the year 2024 it will reach almost $5.5 billion. Rising faster than the GDP, the 
national health expenditure is projected to make up 19.6%, or almost one-fifth, of the 
country’s GDP in 2024.3 
 
Figure 1. National Health Expenditure by Year 
Data taken from CMS (2015) 4 
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Despite the tremendous spending, the quality of US health care is ranked last out 
of 11 developed countries around the world, according to the Commonwealth Fund 
report. The report measured life expectancy, access to care, health care quality, 
efficiency, and equality in Australia, Canada, France, Germany, the Netherlands, New 
Zealand, Norway, Sweden, Switzerland, the United Kingdom, and the United States. The 
US was reported as having the highest costs and lowest performance; compared to the 
United Kingdom which spent $3,406 per person on health care, the US spent $8,508.5  
In addition to the poor outcomes per dollar spent, there is also the problem of lack 
of primary care physicians across the country. In the past decade, the number of primary 
care physicians has decreased by 22%, and by the year 2025 the gap between needed and 
available primary care physicians is estimated to exceed 44,000.6 According to the US 
census, the number of people in US who have insurance reached more than 316 million in 
2014, and it is expected to continue to rise under the new legislation.7 Primary care is 
critical in preventing complicated conditions and curbing the overall costs.  It is of crucial 
importance as the country spent 75% of its annual health expenditure on managing 
chronic conditions in 2010.6 The lack of primary care physicians and the increasing 
number of insured patients in the US will continue to lead the US health care costs 
toward unsustainable levels. There is a dire need to curb the costs and improve the quality 
of US health care.  
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Medication-Related Problems and Their Costly Consequences  
Out of the tremendous sum spent on US health care annually, a major portion is 
due to medications. Retail prescription drug spending alone accounts for $297.7 billion, 
as reported by the CMS. This amount is the result of an unprecedented 12.2% increase in 
2014 compared to the 2.4% growth in 2013. The unusual elevation in medication 
spending can be attributed to the new medications, namely the specialty medications such 
as hepatitis C drugs.8 The similar trend with the specialty medications is seen in the 2014 
Drug Trend Report, which indicates that specialty medications comprise only 1% of all 
prescriptions while accounting for more than 31.8% of total pharmacy spending.9  
In addition to spending a disproportionate amount of money on the acquisition of 
retail prescription medications, Americans are detrimentally affected by the high costs of 
medication misuse. According to the 2011 report by IMS Institute for Health Care 
Informatics, the avoidable costs incurred by medication-related problems account for 
$290 billion.10 More specifically, these problems refer to medication non-adherence, 
delayed evidence-based treatment practice, medication errors, underuse of generic drugs, 
misuse of antibiotics, and mismanagement of polypharmacy.11 From the inappropriate 
use of medications, the US health care experiences a loss of $140 billion from the 10 
million avoidable hospital admissions.12  
The consequences of mismanaged medication therapy are especially dire among 
patients with chronic diseases. According to the Commonwealth Fund’s 2008 
International Health Care Survey, approximately 71% of the adults in US are diagnosed 
with two more chronic conditions,13 and 48% are taking four or more prescribed 
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medications for those chronic conditions.14  In addition, only 33-50% of patients with 
chronic conditions adhere to their prescribed medication regimen,15 and inappropriate 
medication therapy accounts for 32% of adverse events leading to hospitalizations.16 
Adverse drug events (ADEs) are responsible for more than 770,000 injuries and deaths 
each year and up to $5.6 million per hospital, depending on size.17 This estimate relates to 
the cost of the treatment only and does not account for the possible malpractice and 
litigation costs, or the costs of injuries to patients.18 According to the CDC, the US 
annually spends $3.5 billion on extra medical costs due to ADEs, and out of these at least 
40% are estimated to be preventable ADEs.19  
 
Qualification of the Pharmacist 
 The Doctor of Pharmacy (PharmD) degree requires 4 years of professional study 
after at least 2 years of specific pre-professional (undergraduate) coursework.20After 
acquiring the PharmD degree, the pharmacist may choose to pursue a more specialized 
line of work requiring additional years of training. Clinical pharmacists, sometimes 
referred to as the Primary Care Pharmacist Specialists (PCCPS), receive additional post-
graduation training. Although specific regulations may vary across states, at many health 
care facilities such as Kaiser Permanente of Colorado, the PCCPS is required to have the 
PharmD degree, completion of postgraduate year PGY-1 and PGY-2 residencies, and as a 
condition of employment, the board certification in the relevant specialty.21  
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 Board-certified pharmacists work with patients and physicians directly in order to 
ensure that the medications prescribed for patients result in the best possible health 
outcomes. Thus, the pharmacist’s relevant training in the sciences, drug therapy and 
management, and specialized training places them in a unique position to promote 
effective, safe, and affordable use of medications.22 Pharmacists possess the knowledge 
and skills needed to optimize medication therapy and improve clinical outcomes, 
especially for chronic conditions.23 They are suited to work in a variety of health care 
settings and qualified to contribute to the overall goal of increasing the quality and 
reducing the costs of US health care. Namely, with the passage of the new legislation, 
Patient Protection and Affordable Care Act (PPACA), the role of the pharmacist is 
expected to expand in many health care sectors across the country.24  
 
 
THE PATIENT PROTECTION AND AFFORDABLE CARE ACT 
 
On March 23, 2010, President Barack Obama signed the PPACA into law. The 
overarching goal of the new legislation is to increase the insured patient population, 
enhance preventive care, and decrease health care costs.25   
At the patient level, the law provided increased accessibility and affordability of 
health care to US citizens. Some of these provisions relating to the expansion of health 
insurance to individual patients included the implementation of health care insurance 
exchange, expansion of Medicaid, allocation of federal subsidies, and mandate of 
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healthcare insurance.26 Taken together, PPACA is partly responsible for increasing the 
insured patient population to 89.6% in 2014, higher than the rate of 86.7% in 2013.27  
At the institutional level, the two most significant models of healthcare reform 
that emerged from PPACA are known are the Patient-Centered Medical Home (PCMH) 
and the Accountable Care Organization (ACO).25 The two are sometimes considered 
complementary in delivering effective and cost-efficient healthcare services. The PCMH 
emphasizes the coordinated team approach for the care of individual patients while the 
ACO focuses on the collective provider accountability for a group of selected patients.28 
Under these new models, the pharmacist is expected to assume responsibility for the 
medication-related needs of the patient and participate more directly in the effort to 
deliver high-quality and cost-effective health care.25 
 
 
PATIENT CENTERED MEDICAL HOME 
 
The Patient Centered Medical Home (PCMH) is defined as “the model of the 
organization of primary care that delivers the core functions of primary care.”29 The 
Institute of Medicine (IOM) defines primary care as “the provision of integrated, 
accessible health care services by clinicians who are accountable for addressing a large 
majority of personal care needs, developing a sustained partnership with patients, and 
practicing in the context of family and community.”30 The PCMH delivers primary care 
that is patient-centered, comprehensive, coordinated, accessible, and committed to quality 
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and safety. 25 It is an integrative and collaborative approach by the physicians, patients, 
family members, and other members of healthcare that centers on the preferences, needs, 
and values of the individual patient.30 With the collaboration of many health care 
members in the community surrounding the patient, the goal is that the patient receives 
effective preventive care that minimizes the cost incurred by unnecessary medical 
services and future complications.  
 
 
PHARMACISTS IN CURRENT PCMH 
 
The pharmacist can integrate into the PCMH model in a variety of ways. In 
addition, the broad training of the pharmacist prepares them to provide medication 
management and therapy services in not only hospitals and medical offices but in the 
community as well. 
 
Medication Review 
Pharmacists in the PCMH can collaborate with patients, family members or 
caregivers, and the medical home team to create a comprehensive review that addresses 
each patient’s individual medical profile. The careful evaluation of the patients’ 
medication profile can be applied to the current, recently discontinued, and changed 
medications. The pharmacist can assess the potential drug interactions, allergies, dosage 
adjustments, adverse events, therapeutic duplication, cost-effective strategies, and 
	8 
adherence trends.23 Any discrepancies or suggestions by the pharmacist can be discussed 
with the physician and the medical team in order to seek alternative therapies for optimal 
health outcomes. With the prevalence of polypharmacy in patients with chronic 
conditions, the pharmacist can serve as another source of medication scrutiny and 
confirmation, which allows for the other members of the medical team to freely attend to 
other medical issues on hand. 
 
Patient Education at Discharge 
An up-to-date medication profile for patients with chronic conditions is especially 
critical during transitions of care (TOC). Recent studies suggest that the patients’ 
capabilities in managing their medications is sometimes overlooked and overestimated by 
the providers, and many healthcare providers do not adequately educate the patients of 
their medication changes at the time of discharge from the hospital.31 Twenty-three 
percent of patients discharged from hospitals experience an adverse event, and of these 
72% are related to medications.32 The pharmacist can facilitate patient education during 
discharge and provide counseling regarding drug characteristics, adverse reactions, 
mechanism of action, and a written dosing calendar based on the patient’s specific 
regimen.31  
In addition, despite the physicians’ efforts to provide education, patients and 
family members sometimes do not seek adequate clarification due to forgetfulness or lack 
understanding of possible ramifications.13 In hectic environments where the patients are 
anxious to leave and the hospitals are continuously meeting high patient volume, the 
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contributions of the pharmacist can be essential in providing appropriate medication 
counseling at discharge.13 Furthermore, after some of these patients reach the nursing 
homes, the nurses also had difficulty contacting the appropriate medical staff to update 
the medication profile. The delay in communication and organization led to adverse 
outcomes for the patients.13 With the thorough education about the current, discontinued, 
and changed medications, the patients can become more empowered in their management 
of their own medication therapy and experience optimal health outcomes.  
 
Medication Conversion 
Another example of direct pharmacist intervention in medication therapy is the 
medication conversion. While some medication conversion involves changes between 
therapeutic classes used to treat a particular condition, the majority of medication 
conversions involve changes from high-cost to lower-cost therapeutic alternatives.22 With 
the often expensive specialty medications comprising only 1% of all prescriptions while 
accounting for more than 31.8% of total pharmacy spend,9 there is much room for cost 
reductions in medication conversions.  
One study reported annual cost savings of $47,844 from switching from 
nifedipine GITS to amlodipine in 543 hypertensive patients. Considering the cost of 
additional antihypertensive agents discontinued after the conversion to amlodipine, the 
net annual cost savings totaled to $49,578, or a 27% reduction in yearly drug costs of the 
participating institution 33 The medication conversion from nifedipine GITS to 
amlodipine has been supported in literature to be safe and effective among older patients 
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as well as those on multiple antihypertensive medications.34 With rising medication costs 
and availability of various drug therapy options, the clinical pharmacist specialists play 
an integral role in reducing the medication costs while maintaining the quality of care.22 
 
Monitoring    
Another way for the pharmacist to become integrated into the multidisciplinary 
team is through the use of electronic medical records (EMR). The EMR provides a 
convenient way for the pharmacist to monitor drug therapy and obtain real-time clinical 
information regarding the patient. The pharmacist can use the information from the EMR 
to consult with the health care team members and deliver clinical support to the patients 
as necessary.35  
For example, one study reported that having a pharmacist on the rounding team in 
an Intensive Care Unit (ICU) reduced the incidence of ADEs by 66 percent.18 The 
positive clinical impact by the pharmacist could be greatly attributed to monitoring, since 
the patients generally require a greater complexity of monitoring and care in an an 
intensive care setting, the patients generally require a greater complexity of monitoring 
and care.36 According to the Agency for Healthcare Research and Quality (AHRQ) 
anywhere from 28 percent to 95 percent can be prevented by reducing medication errors 
with the use of computerized monitoring systems.17 In addition, AHRQ reports that an 
estimated 84 percent of dose, frequency, and route errors could be reduced with the usage 
of computerized medication order entry. As a consequence, the hospitals have the 
potential to save at maximum $500,000 in direct costs by utilizing the computerized 
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systems.17 The reduction in medication errors leads to the decrease in costs as well as 
rates of mortality and injury caused by preventable ADEs. 
The role of the pharmacist participating in PCMH does not have to be limited to a 
medical practice or an institutional setting. In the community, the pharmacist can monitor 
the efficacy of the patients’ medication use at home in between the primary care office 
visits.23 The complementary knowledge and skills of pharmacists in a PCMH can lead to 
improved patient care and medication use – especially for chronic conditions.37 The 
patients’ adherence can be monitored by the pharmacists and communicated to the 
healthcare providers.38 With vigilant monitoring, the pharmacists can identify any 
discrepancies occurring between points of care transitions such as upon admission or 
discharge from the hospital or emergency departments.23 
 
Medication Plan 
The pharmacist can take an active role in collaborating with physicians as well as 
interacting with patients to improve health outcomes. Pharmacists can work with 
physicians in initiating, modifying, and continuing a particular course of drug therapy.22 
At Community Health Center Inc. in Connecticut, the providers accepted 90% of the 
pharmacist’s recommendations regarding the patient’s medication plan.39 Together with 
the physician, the pharmacist can assess each medication for appropriateness, efficacy, 
and adherence to achieve optimal therapy goals.  
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Outcomes by the Pharmacist in the PCMH Setting 
 One way to measure the clinical impact of the pharmacists’ participation in 
PCMH is the reduction of preventable ADEs. An ADE is defined as an injury resulting 
from the use of a drug, and its subpopulation, the preventable ADEs, are defined as harm 
resulting from an unintentional medication error.40,41 According to Agency for Healthcare 
Research and Quality (AHRQ), the patients who experienced ADEs were hospitalized for 
an average of 8 to 12 days longer than those who did not suffer from ADEs, and this 
resulted in the addition of $16,000 - $24,000 to their total hospital bill.17  
As aforementioned, the ADEs, especially the preventable ADEs, pose a serious 
financial as well as a clinical problem to the US health care. In order to tackle this issue 
and improve health outcomes, more hospitals across the country are examining the 
pharmacists’ contributions in preventing ADEs. One study examining the participation of 
the pharmacist in hospital rounding teams reported a 78% reduction of preventable 
ADEs. In this study, out of the 150 recorded interventions recommended by the 
pharmacist, 147 were accepted by the team. The most common interventions included 
dosing-related changes and recommendations to add a drug to therapy. 42 Another study 
observed that the integration of clinical pharmacists decreased the number of preventable 
ADEs from 26.5 in the control group to 5.7 in the intervention group.43 Studies have 
demonstrated that pharmacists working in integrative team-based care settings have made 
positive contributions. They help optimize appropriate medication use, reduce medication 
related problems, and improve health outcomes.44 Although the financial savings is only 
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one concrete way to measure the positive impact of the contributions of the pharmacist in 
healthcare, the results are clear and aligned with the financial aspect of the PPACA.  
At University Medical Center (UMC) in Tucson, Arizona, the pharmacists 
experienced a redistribution of their services from centralized to ward-based clinical 
activities. The priority for these pharmacists’ clinical services was given to Intensive 
Care Units (ICUs), given the acuity of the patients, the complicated medication regimen, 
and the associated costs of therapies. From mid-October 2003 through February 2004, the 
study concluded that a total cost of $209,000-280,000 would have been incurred by the 
institution without the ICU pharmacist. Of the total interventions recommended by the 
pharmacist, 45% were clarification or correction of orders, 40% were provision of drug 
information, and 26% were recommendations for alternative therapy. In addition, the 
study observed that most of the pharmacist-led interventions occurred during patient care 
rounds and chart-review activities, and their cost savings amounted to approximately 
$80,000 to $110,000.45  
  
Table 1. Intervention Methods and Cost Avoidance of Interventions by the UMC 
Pharmacist. After the data collection, two critical care pharmacists not involved in the 
study reviewed the information, evaluated the probability of ADE avoidance, and 
calculated the risk avoidance costs as reported in scientific literature. 
Table taken from Kopp, Mrsan, Erstad, Duby (2007)45 
 
Clinical Activity No. (%) 
Interventions 
Identified 
Cost Avoidance ($)a 
Evaluator 1 Evaluator 2 
Chart review 52 (40) 87,228 108,203 
Patient care round 50 (39) 78,466 112,617 
Order entry 25 (19) 37,027 53,206 
Medical staff alert 2 (2) 3,198 6,395 
Total 129 (100) 205,919 280,421 
aCalculated using the following formula: (probability x $6,939) x no. interventions 
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Table 2. Time Spent Completing Interventions at UMC 
Table taken from Kopp, Mrsan, Erstad, Duby (2007)45 
 
Time (min) No. (%) Interventions Cost to Institution ($)a 
<15 17 (13) <10 
15-30 83 (64) 10-20 
31-45 22 (17) 21-30 
46-60 1 (1) 31-41 
>60 6 (5) >40 
aEstimated cost to institution for a pharmacist based on an annual salary of $80,000 
 
Table 3. Cost Avoidance of Interventions Involving Adverse Drug Events at UMC 
Table taken from Kopp, Mrsan, Erstad, Duby (2007)45 
 
Probability9,a Cost Avoidance (4)b 
Evaluator 1 Evaluator 2 
0.01 1,279 319.75 
0.1 26,859 21,743 
0.4 89,530 104,878 
0.6 49,881 115,110 
1 38,370 38,370 
Total 205,919 280,421 
aProbability of an ADE occurring in the absence of the intervention 
bCalculation using the following formula: (probability x $6,395) x number of interventions. 
 
 The total cost avoidance made possible by the clinical pharmacist’s interventions 
at UMC seems very auspicious, however, the translation of clinical activities into 
monetary quantities can be difficult. There is a possibility that the cost avoidance 
predicted by the UMC could be overestimated as the results are not actual but calculated. 
For instance, a study done by Kroner et al. compared the projected versus actual cost 
avoidance resulting from the PCCPS-led interventions at Kaiser Permanente Colorado 
and found that the projections had overestimated by an average of 14 percent. Despite the 
overestimation, considerable amount of savings still resulted from the pharmacist-led 
interventions, with a total of 331 completely recorded interventions equaling $176,981 in 
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actual medication cost avoidance (MCA). In addition, the study concluded that the 
projected MCA matched the actual MCA more closely for persistent medication 
conversions with complete cost information. Another important aspect of the study is that 
it was conducted in a primary care setting in which some of the patients changed their 
medications or discontinued them prematurely.22 It may be inferred that the study 
conducted at UMC ICU may be a more accurate portrayal given that the study lasted for a 
shorter amount of time and the patients were consistently given the medications under the 
care of the providers. At any rate, the conclusions are clear: the clinical pharmacists are 
an essential to the health care team in preventing adverse outcomes and consequently, 
reducing the costs associated with such events.45 
Everett Clinic, a multispecialty group practice in Washington State, employed two 
pharmacists in its interdisciplinary care team. The pharmacists worked closely with 
physicians to achieve optimal results from the medication therapy in patients with deep 
vein thrombosis (DVT) and hypertension (HTN).  They optimized medication use, 
improved quality, reduced costs through targeted drug programs, conducted care 
management programs, and positively contributed to the practice in meeting physician 
Pay-for-Performance (P4P) goals. The consequences of their interventions led to a 15% 
increase in the proportion of patients with controlled blood pressure and cost avoidance 
of $450,000 through the initiation of an outpatient DVT therapy program.46 
 Minnesota Project is another example of a successful PCMH model that 
incorporated pharmacists into its interdisciplinary team. In six ambulatory clinics in 
Minnesota, the pharmacist-employees collaborated with the primary care physicians to 
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provide medication therapy services to 285 patients. The program recorded the 
identification and resolution of a total of 637 drug therapy problems relating to HTN and 
hyperlipidemia. The 285 patients in the intervention group received Medication Therapy 
Management (MTM) services by the pharmacists in collaboration with the prescribers, 
compared to the control group which consisted of 126 hypertensive and 126 
hyperlipidemic patients. As a result of the interventions by the MTM services by the 
pharmacist, 71% of the patients under the medication therapy program met the 
Healthcare Effectiveness Data and Information Set (HEDIS) benchmarks for HTN as set 
by the National Committee for Quality Assurance (NCQA) compared to the 59% in the 
comparison group. Furthermore, 52% of the patients participating in the pharmacist-led 
medication therapy met the HEDIS criteria for cholesterol compared to the 30% in the 
comparison group. Altogether, the total health spending decreased from $11,965 to 
$8,197 per person as a result of the pharmacist-led interventions.47 The MTM services 
provided by the pharmacist led to improved clinical outcomes as well as lower total 
health expenditures. 
 Lastly, Table 4 includes some literature review findings from 1994-2003 as 
reported by Rijdt, Willems, and Simoens.48 Although the results may be a bit dated, the 
positive financial and clinical outcomes as a result of the pharmacist contributions are 
clear. The contributions by the pharmacist are expected to continue under PPACA and 
the consequent movement toward collaborative care. 
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Table 4. Pharmacist-Led Hospital Interventions and Their Outcomes 
Data taken from Rijdt, Willems, Simoens (2008)48 
 
Ref No. 
Interventions 
or Patients  
Study 
Period 
(Cost Year) 
Pharmacist’s 
Intervention(s) 
Outcome(s) 
49 259 
interventions 
 
30 days 
(1997) 
Reviewed drug profiles 
only regarding cost-saving 
recommendations 
$5,700 saved on cost-limiting 
interventions, extrapolated to 
savings of $86,000/yr for 
studied wards and of 
$301,000/yr for hospital 
50 193 
interventions 
8 weeks 
(1996) 
Attended rounds and 
advised changes in therapy 
$3,218 saved, extrapolated to 
savings of $25,140/yr 
51 2,879 
patients 
33 periods 
of 9 
months 
(1999) 
Attended rounds $192,681 saved during both 
intervention periods, 
extrapolated to savings of 
$372,384/yr 
52 867 patients 9 months 
(1994-
1995) 
Attended rounds; provided 
DI, pharmacotherapeutic 
consultation, and 
suggestions for alternative 
therapies 
Mean savings of $301 on 
pharmacy costs and $1,654 on 
hospital costs per intervention; 
cost of labor for clinical 
pharmacist not considered; 
decreased LOS by 1.3 days 
42 362 
interventions, 
125 patients 
26 and 40 
weeks 
(1995) 
Attended rounds and 
consulted with focus on 
preventing prescribing 
errors 
58 ADEs prevented (equivalent 
to savings of $270,000/yr) 
43 147 
interventions, 
165 patients 
3 months 
(2000) 
Attended rounds with 
focus on preventing ADEs, 
mostly related to dosage 
changes and addition of 
medication 
78% reduction in preventable 
ADEs 
53 225 patients 3 months 
(1997) 
Reviewed medical records 
to optimize antibiotic 
therapy 
Savings of $386.80 per patient 
based on charges, extrapolated 
to savings of $390,000/yr 
54 238 
interventions 
18 months 
(1999) 
Optimized antibiotic 
therapy 
Differences of 
$4,404/intervention in median 
patient charges and 
$2,642/intervention in median 
patient costs 
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55 199,082 
patients 
1 year 
(1996) 
Managed vancomycin and 
aminoglycoside therapy 
Savings of 6% on total charges, 
8% on drug charges, and 8% on 
laboratory charges; decreases of 
7% in death rate and 12% in 
LOS 
56 16,860 
interventions 
18 months Substituted antibiotics in 
the treatment of CAP 
Savings of $22,316/y; decrease 
of 1.2 days in LOS; lower 
admission rate (2.4% vs 3.4%) 
57 102 patients 172 days 
(1994) 
Reviewed antibiotic 
therapy for switching i.v. 
drugs to oral drugs 
Estimated savings of $5,800/yr; 
costs of operating such a 
program estimated at 
$22,200/yr 
58 7,219 
patients 
2 periods 
of 2 years 
(1996) 
Reviewed prescriptions for 
restricted or nonformulary 
i.v. antimicrobials 
Savings of $291,885. Decline 
of 31% in i.v. antimicrobial 
costs, extrapolated to savings of 
$145,942/yr; mean decreases of 
2.4 days in LOS and 1.67% in 
mortality 
59 172 
interventions 
24 weeks 
(1997) 
Attended rounds, provided 
DI, suggested dosage 
changes, initiated or 
discontinued therapy, 
provided TDM 
Savings of $1,977, extrapolated 
to savings of $9,135/yr 
60 4,959 
interventions 
1 year 
(1999) 
Suggested dosage 
adjustments, route switch, 
pharmacokinetics, TDM, 
and DI 
Savings of $187,852 
61 4,050 
interventions 
10 months 
(1994-95) 
Optimized therapy (e.g. 
DI; provided 
pharmacokinetic 
consultation; adjusted 
dosage frequency, and 
route of administration; 
provided TDM) 
Estimated savings of $464,833, 
extrapolated to savings of 
$557,800/yr; decrease of 372 
days in LOS 
62 2,150 
interventions 
4 months 
(2003) 
Provided TDM, adjusted 
dosages, answered nursing 
questions 
Estimated savings of 
$1,029,776, extrapolated 
savings of $3,089,328/yr 
LOS = length of stay, DI = drug information, ADE = adverse drug event, CAP = community-
acquired pneumonia, TDM = therapeutic drug monitoring, ED = emergency department 
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Table 5. Interventions Conducted by Clinical Pharmacists in Table 4. 
Table taken from Rijdt, Willems, Simoens (2008)48 
 
 
 
 	  
Adjusted dosage for renal and hepatic clearance 
Advised the initiation, discontinuation, or alteration of therapies 
Advised therapeutic drug monitoring 
Detected and prevented pharmacologic and physiochemical interactions 
Detected and prevented prescribing and transcription errors 
Detected, followed up on, and prevented adverse drug events 
Provided drug information to physicians, nurses, and patients 
Conducted drug-use evaluation 
Evaluated drug history 
Followed up on microbial laboratory test results and antibiogram 
Implemented and tracked use of guidelines for correct use of drugs 
Implemented formulary 
Inquired about and counseled patients on admission and discharge drugs 
Optimized dosing and posology 
Participated in physician rounds 
Substituted drugs accordingly to formulary, allergies, contraindications, or costs 
Switched administration route 
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ACCOUNTABLE CARE ORGANIZATION 
 
Many suggest that a PCMH serves as a foundation for the Accountable Care 
Organization (ACO).63 For an ACO to meet its quality and cost goals, it depends on the 
strong preventive and primary care as seen in a PCMH. For a PCMH to be successful it 
depends on the coordination of care as outlined by ACO.42 With pharmacists playing an 
integral role in the PCMH and the PCMH being the foundational element for ACO, the 
role of the pharmacist in the ACO’s efforts to improve health outcomes and reduce 
spending cannot be overlooked. 
The ACO is defined by CMS as a voluntary group of “doctors, hospitals, and 
other health care providers who come together voluntarily to give coordinated high 
quality care to their Medicare patients.”64 As the country battles against the rising 
healthcare costs, the ACO implements a system that incentivizes the cost savings by 
healthcare providers and institutions. The goal of ACO is to deliver high quality health 
care and minimize preventable costs involved in the duplication of services and 
medication errors.64 If the ACO meets the quality standards outlined by the federal 
government and saves money at the same time, then the institution is rewarded back 
some of the savings it achieves for the Medicare program. The monetary incentive behind 
the ACO is attractive because, ideally, the institutions would not only save money from 
its own operating costs but receive additional federal money as a reward.  
A health institution or practice must apply to the government to be awarded an 
ACO contract that delineates the cost-saving goals and quality standards. At present, 
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several forms of ACO exist: the Medicare Share Savings Program (MSSP), the Advance 
Payment ACO Model, and the Pioneer ACO Model. According to the CMS, the MSSP is 
a program that helps certain providers become an ACO. Advance Payment ACO Model 
is a supplementary incentive program offered to some participants within the MSSP, and 
the Pioneer ACO Model comprises some of the earliest adopters of coordinated care. 64  
In addition, under the ACA, many different types of health care settings may 
qualify as an ACO: professional in group practice, networks of individual practices, 
partnerships or joint venture arrangements, hospitals, and other groups of providers as 
deemed appropriate by the US Department of Health and Human Services.65 The 
diversity of ACO settings is advantageous in that each health care institution theoretically 
does not have invest in completely reinventing their existing infrastructure. The providers 
have the option to choose from a variety of ACO settings in order to best address their 
needs and build on their current arrangements.66  
 
Table 6. Quality Standards for MSSP. To share in savings, the ACOs must meet the 
following standards. 
Data taken from CMS and Amara S, Adamson RT, Lew I, Slonim A (2008)67,68 
 
Patient/ 
Caregiver 
Experiences 
• Getting timely care, appointments, and information 
• Physician communication 
• Physician rating 
• Access to specialists 
• Health promotion and education 
• Shared decision making 
• Health status/functional status 
Care 
Coordination/ 
Patient Safety 
• Admissions: Chronic obstructive pulmonary disease/ asthma in 
older adults 
• Admissions: Congestive heart failure 
• Percent of primary care physicians who qualify for electronic health 
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record program incentive payment 
• Medication reconciliation following discharge 
• Screening for fall risk 
Preventive 
Health 
• Influenza immunization 
• Pneumococcal immunization 
• Adult weight screening and follow-up 
• Tobacco use assessment and cessation intervention 
• Depression screening 
• Colorectal cancer screening 
• Mammography screening 
• Hypertension screening 
At-Risk 
Population 
• Diabetes composite: Hemoglobin A1C control 
• Diabetes composite: Low-density lipoprotein control 
• Diabetes composite: Blood pressure control 
• Diabetes composite: Tobacco non-use 
• Diabetes composite: Aspirin use 
• Diabetes mellitus: Hemoglobin poor A1C control 
• Hypertension: Blood pressure control 
• Ischemic vascular disease: Complete lipid panel and low-density 
lipoprotein control 
• Ischemic vascular disease: Aspirin/antithrombotic use 
• Heart failure: Beta blocker therapy for left ventricular systolic 
dysfunction 
• Coronary artery disease composite: Drug therapy for lowering low-
density lipoprotein cholesterol 
• Coronary artery disease composite: Angiotensin-converting enzyme 
inhibitor or angiotensin receptor blocker therapy for patients with 
coronary artery disease and diabetes or left ventricular systolic 
dysfunction 
 
A successful ACO must reduce cost and meet quality standards. In order to avoid 
unnecessary treatments and promote proactive care, ACO emphasizes coordinated care 
and improved communication within the organization.69 
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Cost	Savings	by	the	Pioneer	ACOs	
According to CMS’s 2014 Quality and Financial Performance Results, the ACOs 
continued to improve quality of care and generated shared savings. The year 2014 marks 
the third year for the operation of the ACOs, and just in that year alone the 20 Pioneer 
ACOs and 333 Shared Savings Program ACOs together generated more than $411 
million in saving. The Pioneer ACOs showed improvements in 28 of 33 quality 
standards, and the Shared Savings Program ACOs improved on 27 of 33 quality 
standards. Between the passage of the PPACA in 2010 and January 1, 2015, more than 
420 Medicare ACOs have been established across the country serving more than 7.8 
million Medicare beneficiaries. The growth of ACOs, as well as the monetary savings, is 
expected to continue in the future years.70    
 
Figure 2. Collective Savings Generated by the Pioneer ACOs during the Years of 
Operation 
Data taken from CMS (2015)71 
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Figure 3. Collective Savings Held Under the Target Spending and the Earned 
Performance Payments 
Data taken from CMS (2015)71 
 
 
 
 
 
 
 
 
 
 
As the health care institutions seek ways to reduce their spending, increase their 
revenue, and deliver quality services, more organizations are enrolling into ACO models. 
The currently established ACOs produce real savings, and many institutions receive a 
share of their savings back.  
Taken together, the objective of the ACO is to actualize a culture of collective 
accountability and implement effective strategies to improve health care outcomes and 
reduce spending for the participating groups of providers. In order to fully reap the 
clinical and financial benefits of the ACO, the participating groups must invest in a 
wholesome transformation that will serve as a stable foundation for the future. Leading 
an ideal ACO, in summary, requires much more than simply meeting the quantitative 
standards as outlined by the government. In order to create a sustainable environment of 
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aligning care, reducing costs, and increasing quality of care, each ACO needs to examine 
its needs, coordinate care among the providers, and lead its everyday operations with the 
mission of ACO at the forefront. 
 
Table 7. Required Competencies for ACOs  
Data taken from Bennett (2012)66 
 
Leadership At least 75% control of the ACO’s governing body must be 
held by ACO participants. 
IT infrastructure for 
population management 
and care coordination 
ACOs only have to report on the quality measure “Percent of 
PCPs who Successfully Qualify for an HER Incentive 
Program Payment”; CMS will double-weight this quality 
measure. 
Infrastructure for 
monitoring, managing, 
and reporting quality 
ACOs will report on 33 quality measures instead of 65; 
measures are standard across all ACOs. There will be no 
flexibility for different quality measures in different regions. 
For the first year of the ACO program, ACOs must have 100% 
reporting on all 33 measures before they are eligible to share 
in any savings. 
Ability to manage 
financial risk 
ACOs share their savings but also a great deal of risk 
depending upon which SSP model is used. 
Ability to receive and 
distribute payment or 
savings 
ACOs provide two models: one-sided and risk-shared savings 
model (this option is available during an ACO’s initial three-
year agreement period) and two-sided risk-shared savings and 
losses model. 
Resources for patient 
education and success 
ACOs must define, establish, implement, and periodically 
update processes to promote patient engagement. 
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PHARMACISTS IN CURRENT ACOs 	
 Because the current quality standards for the MSSP ACOs do not include savings 
in pharmaceuticals or improvements in quality related to drugs, many ACOs have not 
formally incorporated pharmacists into their interdisciplinary teams. However, those that 
have incorporated pharmacists in their health care teams have benefited from numerous 
improvements in health outcomes and cost savings.68  
Some of the medication-related responsibilities of pharmacist in ACOs may 
include drug therapy/adherence clinics, medication reviews/reconciliation, and drug 
utilization reviews and identification of under- or over-medicated patients.72 MTM 
services offer a guide to ensure appropriate medication use, especially in the management 
of patients with chronic disease.69 However, the impact of the pharmacist in an ACO may 
extend beyond those that are medication-related, especially as more health care settings 
embrace the interdisciplinary team care. Pharmacists often develop close relationships 
with the patients, and the positive patient interactions can help the ACO achieve the goal 
standards in the Patient/Caregiver Experience portion of the ACO quality measures. In 
addition, as aforementioned in the PCMH section, the pharmacist can facilitate the 
medication review during hospital discharge and TOC points. Immunization of influenza 
and pneumonia is another area that the pharmacist can contribute to the ACO quality 
standards. Furthermore, the pharmacist can provide services that meet various other 
quality measures such as in the management of diabetes and blood pressure as well as 
many preventive health interventions.68  
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 At El Rio Health Center in Arizona, one of the nation’s largest nonprofit 
community centers, the clinical pharmacists are certified to conduct Annual Wellness 
visits (AWV) to the patients under the ACO arrangement. A retrospective study was 
performed examining all of the patients at El Rio Health Center between the months of 
October through December 2013. The report concluded that the recommendations made 
by the pharmacists had a high acceptance rate among both the physicians and the 
patients.73 
 
Table 8. Interventions Performed by Pharmacists at El Rio Health Center ACO 
Table taken from Alhossan, Kennedy, Leal (2016)73 
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 In addition, as a result of the interventions by the pharmacist, the clinic was able 
to generate $22,000 from the visits alone as well as $36,379 from the related preventive 
care services that followed. 73 
 
 
Table 9. Revenue From AWV and Services Provided 
Table taken from Alhossan, Kennedy, Leal (2016)73 
 
 
 
Table 10. Revenue From Other Services Rendered During AWV 
Table taken from Alhossan, Kennedy, Leal (2016)73 
  
	29 
 The study confirmed that the clinical pharmacists are a valuable asset to the ACO 
team in conducting clinical interventions, offering preventive primary care services, and 
generating revenue for the ACO. Particularly, given that a major portion of the AWV 
involves the evaluation of medication usage and adherence, the clinical pharmacists at El 
Rio Health Center are able to deliver high quality health care to the patients and ensure 
their optimal usage of medications.73 
 Fairview Health Services is a health system based in Minneapolis, Minnesota that 
currently participates in the CMS Pioneer ACO model. Here, the pharmacists spend two 
days a week providing Medication Therapy Management (MTM) services to eligible 
patients at primary care settings. They work collaboratively and also autonomously to 
review and modify medication therapy for approximately 20 chronic conditions. Since 
the establishment of its MTM services in 1997, the program has served over 15,000 
patients and resolved nearly 80,000 medication-related issues. Fairview’s pharmacist-led 
MTM services have reduced the health care costs, improved clinical outcomes in patients 
with diabetes and asthma, and allowed for efficient operation of the interdisciplinary 
team by freeing up the primary care providers.68 
 The Norton ACO in Kentucky is another ACO that successfully utilizes the 
contributions of the pharmacist. The pharmacists here focus on reducing the readmission 
rates for congestive heart failure by examining the patients’ clinical profiles for 
omissions, errors, or any other inconsistency in medication. In addition, the pharmacist 
provides patient education at discharge. These pharmacist-led directives have helped 
identify an average of 1.5 medication discrepancies per patient and affirm the positive 
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health outcomes made by the pharmacist in an interdisciplinary team model.74 
 Another ACO that has incorporated pharmacists into the multidisciplinary team is 
Baylor Health Care System. Through chronic disease management programs and medical 
homes, the pharmacists provide preventive health screening, coordinated care services, 
counseling on the management of chronic conditions, weight management, and smoking 
cessation programs. In addition, the pharmacists also help patients obtain accessible 
medications from pharmaceutical manufacturers as well as operate a medication 
assistance programs for patients with a high risk of hospital readmissions.75 
 CIPA, a physician group practice in New York, is another promising model of 
ACO that recognizes the contributions of the pharmacist and integrates pharmacists into 
its practice. The pharmacists work closely with 20 of CIPA’s 900 providers in direct 
patient care, and additionally the pharmacist provides medication information to the 
providers as needed. CIPA is obtaining grants and other means of funding in order to 
continue offering pharmacist-led services to its patients.75 
 Several other organizations incorporate pharmacists in their ACO models. These 
include Vermont Community Health System as well as the Carillion Clinic in Virginia, 
where the pharmacists provide services to patients with complicated medication profiles 
and chronic conditions. As ACOs across the country expand and grow, pharmacist 
involvement is also expected to grow. 74,75 
The high rates of medication misuse, non-adherence, and adverse drug events all 
add to the preventable and unnecessary medical costs. In efforts to optimize the 
medication therapy, pharmacists could be a valuable asset to the ACO team.68 The 
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addition of pharmacists within ACO healthcare teams will be crucial to achieving CMS 
quality standards.76 With the growth of ACO, the pharmacy involvement is expected to 
increase in the upcoming years.75 Cost savings can be realized from a culture of 
collective accountability, which aligns the incentives between the physicians and the 
ACO. 
 	
VALUE-BASED PURCHASING MODELS 	
 
Under the economic and social pressures, the US healthcare platform is 
experiencing a shift from the individual physicians to a system of professionals as 
characterized by ACOs. The government and insurance companies are seeking ways to 
deliver high-quality care at lower costs. They are attempting to move away from Fee-for-
Service (FFS) payment model, which reimburses providers simply by the number of 
procedures performed. 69 The FFS model is counterproductive to the nation’s efforts to 
curb spending since the providers are incentivized only by the number of services 
performed. The focus on the quantity quickly adds to the climbing health care costs and 
places very little accountability on individual providers.  
Instead, the government is seeking ways to incentivize quality, or the “value,” of 
the health care services. The payment system that is widely being adopted is called 
Value-Based Purchasing (VBP), more specifically the pay-for-performance (P4P) model. 
The CMS defines value-based health care purchasing as care that is financially linked to 
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quality outcomes.77 Under the P4P model, the payment to the provider is partly 
determined by the quality and value of the services performed.78 The provider can be 
rewarded or penalized financially in part by the measures of patient experience. The goal 
of P4P is to reward healthcare providers for creating a more humane and respectful 
atmosphere for the patients rather than simply providing the quantity of healthcare 
services. 79 By 2018 CMS anticipates that at least 90% of all Medicare fees will be by 
VBP. Moreover, by this date CMS anticipates that over 50% of these VBP will be found 
within ACOs.77,80 
The reformed payment model serves as an additional incentive for providing 
high-quality services while operating at manageable costs. Together with the F4F model, 
the ACO places emphasized accountability on the providers and responsibility to provide 
high-quality services at reduced costs. As more provider groups focus on improving the 
quality of care delivery and adopt the value-based purchasing model, the pharmacists can 
expect to play an integral role in medical homes to improve chronic disease and 
medication therapy outcomes, lead medication adherence programs and reduce 
medication-related hospital readmissions.23 
The pressures for provider accountability, in both the growth of ACOs and 
implementation of VBP, are likely to increase in the future.66 With the nation battling to 
reduce the unsustainable and rising costs of US health care, pharmacists are in the 
position to become an increasingly critical asset in PCMH as well as ACO. 				
	33 
MEDICATION THERAPY MANAGEMENT 
  
MTM is defined as a distinct service or group of services that optimize 
appropriate medication use and health outcomes for the patient.81 MTM services are 
characterized by a group of pharmaceutical care interventions in which a qualified 
pharmacist works directly with the patients, prescribers, and other health care providers 
in order to achieve maximum intended therapeutic outcomes for the patient.82 Although 
not specifically created under the PPACA, the MTM services provide the framework for 
medication management for the providers and pharmacists in PCMH and ACO. In simple 
terms, MTM often serves as the guidelines to achieve optimal medication use in a variety 
of health care settings.  
In 2003 the Medicare Modernization Act was first introduced, requiring that 
Medicare Part D meet federal standards with regard to cost control and quality 
improvement.83 It was not until 2006 that the Centers for Medicare & Medicaid Services 
required the implementation of MTM services to Medicare Part D patients who are at the 
highest risk for drug therapy problems.82 These high risk patients are identified as those 
having chronic diseases and high drug costs.84 The legislation did not delineate MTM as 
specifically the responsibility of the pharmacist, but it did expand the involvement of the 
pharmacist in direct patient care.  
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Table 11. Medication Therapy Management Components as Described in Section 
3503 of the Affordable Care Act35 
Table taken from Matzke (2012)35 
	
   
 
As aforementioned, although MTM was not initially created under PPACA, the 
adoption of its ideals has become more prevalent with the passage of PPACA. A major 
part of its implementation is within the ACOs. Many emerging ACO groups have begun 
to implement pharmacy services using MTM in an effort to reduce pharmacy costs and 
improve health outcomes.76 In addition, there is speculation that soon MTM will be 
expanded to a broader Medicare patient population under PPACA. The federal funding 
will also promote the establishment of community-based, multidisciplinary health care 
teams that incorporate the pharmacist-led MTM services into the primary care services. 
• Formulating a medication treatment plan according to therapeutic goals agreed 
upon by the prescriber and the patient or caregiver or authorized representative of 
the patient 
• Selecting, initiating, modifying, recommending changes to, or administering 
medication therapy 
• Evaluating the response of the patient to therapy, including safety and 
effectiveness 
• Performing an initial comprehensive medication review to identify, resolve, and 
prevent medication-related problems, including adverse drug events 
• Quarterly targeted medication reviews for ongoing monitoring, and additional 
follow-up interventions on a schedule developed collaboratively with the 
prescriber  
• Providing education and training designed to enhance the understanding and 
appropriate use of the medications by the patient, caregiver, and other authorized 
representative 
• Providing information, support services, and resources and strategies designed to 
enhance patient adherence with therapeutic regimens 
• Coordinating and integrating medication therapy management services within the 
broader health care management services provided to the patient 
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Moreover, the funding will allow for the pharmacist to provide additional MTM services 
in the treatment of chronic conditions based on patient assessment and five “core 
elements” of MTM services.85 
 
Table 12. Five core elements of MTM 
Data taken from Bennett et al. (2008)38 
 
 
• Medication therapy review (MTR) 
• Personal medication record (PMR) 
• Medication-related action plan (MAP) 
• Intervention and/or referral 
• Documentation and follow-up 
 
Currently, the MTM services are delivered to both public and private sectors.38 
The services may be provided at the hospital, primary care clinics, drug therapy clinics, 
brown bag programs for post hospital discharge patients, or prescription drug adherence 
clinics.68 As a whole, MTM aims to prevent medication error, improve reliability of 
healthcare delivery, reduce hospital readmissions, and enable patients to take an active 
role in medication and healthcare self-management.86 The pharmacists participating in 
MTM services are responsible for assessment of drug therapy, adherence monitoring, 
active communication with prescribers, and identification of any gaps in care.68 
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COMMUNITY PHARMACIES 		
As the scope of healthcare continues to transform from product-focused to 
patient-focused care, the role of community pharmacists is transforming also. In the past, 
the role of the community pharmacists primarily involved acquiring, preparing, and 
dispending the drugs. Today, the pharmacist is more actively engaged in patient-centered 
care.  Because the pharmacists are accessible, have knowledge on medication, and are 
commonly close to the patients, they have a lot to offer and are in the optimal position to 
offer effective MTM services.87 
An area of increasing participation by the community pharmacist is prevention 
and wellness. Section 4202 of the PPACA outlines the evaluation of community-based 
prevention and wellness programs for Medicare beneficiaries and promotion of 
immunizations for children, adolescents, and adults.88 Over the past decade, pharmacists 
have administered millions of vaccinations and played an integral role in various 
immunization campaigns across the country. 35 The new law authorizes the expansion of 
funding and allows for the active involvement of the pharmacist in the prevention and the 
wellness of the society.  
According to a recent study, the community pharmacy-based TOC programs that 
utilize MTM services have shown to decrease hospital readmission rates. The study 
involved 90 patients and 9 Kroger Pharmacies in western Cincinnati. Within one week 
after the discharge from one of the two local hospitals, the patients were recruited into 
either the control group that received no MTM services or the intervention group that 
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received MTM services by the community pharmacist. The services included 
reconciliation of the patients’ medications, identification of drug therapy problems, 
recommendation of drug therapy changes, and self-management education for the 
patients.  As a result of this patient-pharmacist interaction, a total of 210 interventions 
was made. Then, 30 days after the date of discharge, the rate of hospital readmission was 
collected through phone surveys. The study concluded that those who received MTM 
services by the community pharmacist had an average hospital readmission rate of 6.9% 
compared to 20% for those in the control group. Although there was not much difference 
in the level of patient satisfaction between the control and intervention groups during the 
TOC process, the result was clear. The patients who received MTM services by the 
community pharmacist experienced a reduced hospital readmission rate compared to 
those who did not.89 As much of the preventable adverse health outcomes as well as 
avoidable costs are incurred by medication-related problems10, the pharmacists can play a 
critical role in health care. Moreover, the community pharmacists can serve to bridge the 
gap in patient care and communication outside the hospital. Effective health care does not 
have to terminate once the patient is discharged, given that the qualified pharmacists are 
available in the community outside the doctor’s offices. 
Another part of the MTM services includes targeted medication interventions 
(TMI). TMIs are interventions focused to increase medication therapy adherence and 
resolve any conflicts in care as means of preventive measures and delivery of high quality 
care. TMIs can be initiated either automatically by the online MTM platform or manually 
by the individual who identified the problem. The online MTM platforms connect the 
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insurance companies with the pharmacists regarding the entry of identification, 
resolution, and reimbursement of MTM services. A summary of TMI performed by the 
community pharmacists is shown in Figure 4. In order to resolve a TMI, the pharmacist 
needs to contact the patient in order to address adherence issues or be offered education 
and counseling. At other times, the prescriber needs to be contacted in order to initiate 
addition or change to the medication to a more cost-effective alternative.87  
 
Figure 4. Flow chart for TMI 
Figure taken from Melody, Shah, Patel, Willey (2015)87 
 
A study conducted in 2015 examined the implementation of a student pharmacist-
run TMI program. The conclusions indicated the types of TMI resolutions, the 
difficulties, as well as the additional revenue generated from the reimbursements using 
the online MTM platform. Of the total TMIs conducted, the majority was due to the 
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underuse of the medication, which amounted to more than 70 % of the total interventions. 
Consequently, the resolution of medication underuse generated the highest amount of 
revenue. The study confirmed the dire need for improvement in patient medication 
adherence as well as delineated the revenue generated from each resolved TMI. 
 
Figure 5. Revenue Generated Per Hour of TMI 
Figure taken from Melody, Shah, Patel, Willey (2015) 87 
 
 
 
There are many ways by which the community pharmacists can participate in the 
direct care of the patients experiencing chronic medical conditions, transition between 
chronic and acute care, emergent care, and long-term care.87 Despite the lack of concrete 
guidelines for structure and payment models that support the permanent establishment of 
advanced MTM services in community pharmacies, Section 4206 authorizes the funding 
of pilot demonstration projects that successfully implement individualized wellness plans 
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at community health centers.35  
Among the most well-known and successful community pharmacy models, the 
Asheville Project began in 1996 in the City of Ashville, North Carolina. Under the 
initiative, the community pharmacists managed the patients’ chronic health conditions, 
such as diabetes, asthma, HTN, and high cholesterol, by setting and monitoring treatment 
goals and assessing laboratory values and medication adherence. The project developed a 
network of community pharmacies that participated in direct patient care, and as a result 
produced numerous improved health outcomes. The study reported improved A1C levels, 
improved immunization rates, lower total health care costs, fewer sick days, and 
increased satisfaction with pharmacists’ services.90 Following the success of the 
Asheville Project, few other community pharmacy models have been developed in 
replication, such as the Diabetes Ten City Challenge.35  
The Diabetes Ten City Challenge (DTCC) was a multisite community pharmacy 
management program for patients with diabetes that took place in 2006-2007. Across 10 
cities in South Carolina, Maryland, Illinois, Colorado, Georgia, Hawaii, California, 
Wisconsin, Pennsylvania, and Florida, 573 diabetic patients received self-management 
care services by the pharmacist within a collaborative care model. As a result, the annual 
total health care costs were reduced by an average of $1,079 per patient compared to the 
projected costs if the DTCC had not been implemented. Clinically, over the mean period 
of 14.8 months of the program, the participants recorded a mean glycosylated 
hemoglobin decrease from 7.5% to 7.1%, a mean low-density lipoprotein cholesterol 
decrease from 98 to 94 mg/dL, and a mean systolic blood pressure decrease from 133 to 
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130 mmHg. Additionally, the influenza immunization rate increased from 32% to 65%, 
the eye examination rate increased from 57% to 81%, and the foot examination rate grew 
from 34% to 74% as performed by the pharmacist. The DTCC study was an important 
demonstration in pharmacist-led community collaboration in that during the first year 
alone, the community was able to obtain measurable improvements in the management of 
chronic diseases, increased rates of self-management and goal-setting, as well as higher 
satisfaction with diabetes care. Lastly, more than 97% of the surveyed patients reported 
the services provided by the pharmacist to be satisfactory or very satisfactory.91 
 Between July 2009 and May 2010, a CMS demonstration project in Connecticut 
served 88 Medicaid patients. Here, the pharmacists offered on-site patient care services 
that included MTM services for smoking cessation, hypertension, asthma, diabetes, pain 
management, and anti-coagulation. The medication management program involved the 
preparation of active medication profiles, assessment of appropriateness, effectiveness, 
safety, and adherence of medications, and identification of any drug therapy problems. At 
the end of the program, the pharmacists identified 917 drug therapy problems and 
resolved nearly 80% of them after four encounters with the patients. The result of these 
interventions amounted to an estimated annual saving of $1,123 per patient on 
medication claims and $472 per patient on medical, hospital, and emergency department 
expenses. Clinically, the program reported a 50% increase in the number of patients who 
achieved their therapeutic goals.39 
 There are many ways by which the community pharmacists can interact with 
patients and providers to provide positive health outcomes. With the culture of the US 
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health care changing under the PPACA, the pharmacists are contributing in more diverse 
and flexible ways than ever before. Given the versatility of the pharmacists’ work settings 
and their responsibilities, there are more ways for them to directly participate in the 
maintenance and promotion of public wellness.  
 
 
DIFFICULTIES 
 
Under the PPACA, the PCMH and the ACO address two different aspects of 
healthcare reform; PCMH leads the primary care reform while ACO delivers the system 
reform. Despite the two models’ theoretical aligning and overlapping ideals, the 
discussion surrounding payment of physicians within each model remains distinct.92 In 
the PCMH, a major barrier to pharmacy-provided primary care services is the lack of 
reimbursement models.25 Some providers simply cannot afford to hire pharmacists, and 
additionally, there is no concrete business model to support the pharmacists’ involvement 
in direct patient care. 39 The payment systems for pharmacist-provided care services are 
variable and often have been grant-funded projects.23 In addition, pharmacy-specific 
current procedural terminology (CPT) billing codes exist, but they are infrequently used 
as a payment option for medication therapy services.23 There is increasing pressure for 
the pharmacists to be compensated for predispensing prescription review, patient 
education and consultation, and optimal medication-therapy prescribing and 
management.93 Without concrete payment reform that supports the integrative primary 
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care teams, the primary care practices within ACOs will struggle to transform into 
successful medical homes.92 
Another barrier against achieving maximum medication therapy by the 
pharmacist in the PCMH setting is the limited access to patient information. An 
integrated and shared EMR system helps the pharmacist monitor the patients’ medication 
therapy in real-time and make any adjustments as necessary with the collaboration of the 
provider.93 In the absence of the computerized physician order entry (CPOE) system, 
errors occur more frequently.94 The lack of automated electronic systems may be 
especially burdensome in the rural areas where the access to the internet may be 
limited.93 The centralized and computerized services are critical as they facilitate the 
communication among the providers, ensure timely delivery of care, and provide means 
of accountability of the care provided. 
 Relating to the topic communication, another difficulty is the lack of cooperation 
among the prescribers, pharmacists, and the patients as seen in a study involving the 
student pharmacist-run TMI services. Of the total TMIs in which either the prescriber or 
the patient had to be reached, more than half of the attempts were futile due to the 
inability to reach them.87 This reflects the serious and dire need for improved 
communication among the providers, pharmacists, and patients as patient care and 
medication therapy do not end when the patients leave the doctors’ offices. In order to 
ensure optimal clinical outcomes by medication therapy, the cooperation within the 
health care community surrounding the patient is critical. 
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Figure 6. Acceptance Rates of TMI 
Figure taken from Melody, Shah, Patel, Willey (2015)87 
 
  
 
 
 
 
 
 
 
 
 
 
In addition, within the PCMH setting, some pharmacists have commented that 
more recognition and appreciation for the pharmacist’s services are needed. For example, 
one study indicated that pharmacist often attempted to predict the required medications 
for the patients at the time of discharge in order to save time preparing the patient 
medication education. In addition, within the interdisciplinary team, the pharmacists 
found that nurses sometimes failed to administer medicines without being given an 
appropriate rationale.13 With the role of the pharmacist expanding in many institutions 
across the country, the need for communication and clear expectations among the 
members of the PCMH cannot be overstated.13  
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Table 13. Barriers that Pharmacists face in Improving Medication Therapy 
Data taken from Zarowitz et al. (2010)93 
 
• Inadequate, erroneous, or compromised decision-making by the prescriber 
• Lack of integrated and shared electronic medical records and computerized order-
entry systems 
• The patient’s inability to afford the medication or part of its cost (e.g. copayment) 
• Limited access to medical information and technologies that improve medication 
safety particularly during transitions of care 
 
Because the PCMHs and ACOs are intricately tied together and the success of an 
organization’s ACO ultimately depends on the success of the PCMH, many of the 
aforementioned difficulties surrounding the PCMH extend to the ACO.35 However, there 
are additional difficulties that can thwart an ACO from meeting the quality standards. 
 As the goals of the ACOs are explicit and immediate in the ACO contracts, some 
ACOs may be tempted to establish changes that produce only short-term results. For the 
realization of maximum integration of the pharmacist and its reaped benefits, some ACOs 
need to seek ways to transform the community of the health care. For some ACOs, these 
are accomplished by de-centralizing the role of the pharmacist, raising more public 
awareness on provider accountability, and aligning the ACO’s incentives with the 
institution’s mission for high quality at lower costs.  
In addition, as many providers continue to be reimbursed by FFS, many ACOs 
may operate at high costs.92 For example, according to the Hospital Consumer 
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Assessment of Healthcare Providers and Systems hospital version survey, the hospital 
that have higher operating costs, on average, also have higher levels of patient 
satisfaction. In other words, spending more money is counterproductive to the financial 
goals of ACO, but at the same time it may lead to higher patient satisfaction levels.95 This 
may pose a problem given that the final evaluation of the ACOs depends on both the 
levels of patient satisfaction as well as the reduction of operating costs. By incorporating 
the value mission of the ACO into the profound infrastructure of the organizations and 
creating a culture of coordinated care, long-term effects will be felt and appropriate 
measure will be embraced for any necessary expansions in the future.  
For the community pharmacists, more time needs to be spent on counseling the 
patients rather than labeling, coding, and assembling of prescriptions. The overall goal of 
a pharmacy should be that every patient not only receives medication but that each 
patient leaves with the ability to manage the medication safely, effectively, and cost-
efficiently. The success of patient interactions at the community pharmacy depends on 
the cooperation with physicians, remuneration, pharmacy layout, patient expectations, 
amount and quality of pharmacy staff and support.96 
 Another difficulty that pharmacists, as well as other health care providers, face in 
fully embracing the provisions of the PPACA is the public perception and awareness of 
the PPACA.  
According to the Kaiser Health Tracking Poll from January 2016, the issue of 
health care and health insurance remains one of the top priorities for the American 
citizens. The survey reported that among those who registered for the 2016 elections, 
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nearly quarter (23%) considered PPACA extremely important and 4% chose it as their 
most important issue at this point in the elections. 
 
Figure 7. PPACA Remains One of the Top Concerns to American Voters as of 
January, 2016 
Figure taken from Kaiser Health Tracking Poll (2016)97 
 
Particularly, according to the poll results, 74% of the Democratic registered voters 
labeled health care as “the single most important factor” or “a very important factor” in 
their vote for the next president of the United States. Although the Independent and 
Republican registered voters followed behind, with 63% and 54% respectively, the 
survey results indicated that PPACA remains one of the main concerns for more than half 
of the American voters.
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Figure 8. Percentage of the Registered Voters by Political Parties Who Consider the Issue of Health Care “the Single 
Most Important Factor” or “a Very Important Factor” in the 2016 Elections 
Figure taken from Kaiser Health Tracking Poll (2016)97 
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In addition, much of the nation still suffers from the division and confusion 
surrounding the PPACA. For example, regarding President Obama’s veto against the bill 
that would repeal PPACA, the survey showed that an equal number of Americans (39%) 
are aware of the recent political developments as are unaware of it. 
 
Figure 9. Awareness of President Obama’s Veto 
Figure taken from Kaiser Health Tracking Poll (2016)97 
 
 
 
In addition to the public’s insufficient awareness surrounding the PPACA, the 
negative perceptions of the law by the public persists. Forty-one percent of the 
participants hold a favorable view of the law while the majority, 44%, holds an 
unfavorable view. A similar trend has persisted for several months. 97	
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Figure 10. The Persistence of PPACA Opponents 
Figure taken from Kaiser Health Tracking Poll (2016)97 
 
  
In order for the country to transform the state of health care to the high-quality 
and cost-effective collaborative approach, it is essential that the public fully understands 
the stakes and their role. It is not an easy task to call for a change of the status quo, 
especially in the health care sector that is often reluctant to change.96 Major 
improvements to overall US health care cannot be accomplished solely at the level of the 
health care providers; the cooperation of the public is also necessary.  
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 Lastly, it is important to note that, while medication management is one area that 
is certainly open to cost-saving and quality improvement measures, it is not the only 
aspect of the US health care system that needs reform. According to Consumer and 
Provider Perspectives, the majority of the polled providers believe that there is much 
room for improvement in the areas of tort reform and preventive care.99 As US health 
care becomes more collaborative, the pharmacist’s expertise and training may be utilized 
in many of the areas that are conducive to change.  
 
Figure 11. Controlling and Reducing Health Care Costs as Polled by Providers 
Figure taken from Booz Allen Hamilton (2014)99  
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CONCLUSION 
 
 The US health care expenditures are staggering, and there is a collective call for 
action to improve the quality of health care and minimize the costs. Although some 
legislation has been in effect for years to allow for a degree of health care reform, such as 
the Medication Therapy Management services, the US has experienced an unprecedented 
transformation in health care since the passage of the Patient Protection and Affordable 
Care Act in 2010. The result is the movement toward an environment of collaborative 
team models that places increased accountability on the providers for the value of the 
services delivered. With the pressure to deliver high quality services at low cost, many 
health care organizations are seeking innovative ways to fully utilize its workforce and 
coordinate care among the providers, as seen in the Patient Centered Medical Homes and 
the Accountable Care Organizations. As the new patient-centered care models embrace 
the integration of the health care community around the needs of the patient, pharmacists 
are engaging more actively in direct patient care. In addition, medication management 
represents one area that is amenable to cost-effective changes. The need for primary care 
and preventive health is dire, and the pharmacist is proving to be an integral force in 
many interdisciplinary care teams across the country. The comprehensive training and the 
diversity of work settings allow the pharmacist to offer medication-related services, as 
well as other clinical services, in numerous health care environments to produce positive 
health outcomes and generate cost savings.  
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Since the passage of the PPACA, the nation has remained divided in its opinion 
toward PPACA. However, there is overwhelming support for the delivery of primary 
care, one aspect of PPACA. Thus, as contributing members of the health care 
community, the pharmacists have the opportunity and responsibility to fully embrace the 
change and become an important part of the progressive movement that will impact the 
US health care for many future generations.  
 
 
Figure 12. Nation’s Favorable View Toward Coordinated Delivery of Primary Care 
Figure taken from Matzke (2012)35  
 
 
In summary, the current state of US health care continues to evolve, and the role 
of the pharmacist continues to expand in order to meet the increasing demands for high-
quality, cost-effective health care. 
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